Computerized impedance plethysmography in the diagnosis of delayed deep vein thrombosis after total hip replacement.

Although noninvasive techniques have been extensively evaluated in the diagnosis of deep vein thrombosis (DVT), few data exist about the role of computerized impedance plethysmography (CIP) in the diagnosis of delayed DVT after surgery, when patients are at home and the risk of DVT is still high. The aim of this study was to evaluate the reliability of CIP in the diagnosis of proximal and distal delayed DVT in both symptomatic and asymptomatic patients who had undergone elective total hip replacement (THR). Bilateral CIP of lower limbs was performed in 61 patients on days 5, 9, 15 and 45 after THR; for comparison, ascending phlebography was performed on days 45 after THR in all patients on the operated limb or on the limb with positive results on CIP. The overall rate of DVT diagnosed by phlebography was 16.3% (10/61). The sensitivity and specificity of CIP for all DVT were 20% and 98%, respectively, while the accuracy was 85%. The results were not influenced by the presence of symptoms or signs of the lower limbs. Similar results were obtained when considering proximal DVT only. In conclusion, the low sensitivity of computerized impedance plethysmography means that it cannot be used in screening for delayed deep vein thrombosis after total hip replacement, in both symptomatic and asymptomatic patients. However, because of its high specificity, when the results of computerized impedance plethysmography are positive phlebography should be performed to confirm the diagnosis of deep vein thrombosis.

Long-term survival in primary amyloidosis of the laryngotracheobronchial tract by treating complications only.

Primary amyloidosis limited to the laryngotracheobronchial tract is relatively uncommon; therefore, knowledge of survival in these patients is poor and consensus regarding appropriate therapy unreached. The case is reported of a patient affected by primary amyloidosis limited to the laryngotracheobronchial tract who had a long survival and a good quality of life after only medical and neodymium-yttrium aluminium garnet (Nd-YAG) laser therapy. The patient had amyloidosis first detected in the larynx, which, 4 yrs later, progressed to involve the tracheobronchial tract, without pulmonary involvement. The patient was treated three times with Nd-YAG laser to obtain the recanalization of obstructed bronchi, with evident improvement of symptoms and pulmonary function. In conclusion, laryngotracheobronchial amyloidosis survival may be lengthened and quality of life made more acceptable by treating potential complications only.

Value of thrombin-antithrombin III complexes in major orthopedic surgery: relation to the onset of venous thromboembolism.

This study evaluated (a) the possible changes of plasma levels of thrombin-antithrombin III complexes during hospitalization to predict venous thromboembolism in patients undergoing elective total hip replacement and (b) the sensitivity and specificity of thrombin-antithrombin III complexes in the late incidence of deep vein thrombosis when these patients are discharged from the hospital. In 50 consecutive patients (18 men, mean age = 63 +/- 8 years) a venous blood sample was obtained from each patient before surgery and postsurgery on days 5 +/- 2, 9 +/- 2, and 45 to evaluate the thrombin-antithrombin III complexes by the enzyme-linked immunosorbent assay as a part of a larger surveillance program. Six of 50 patients developed deep vein thrombosis, diagnosed by phlebography on the 45th day postsurgery. From the day before until the ninth day after surgery, mean values of the thrombin-antithrombin III complexes increased to a greater extent in patients with deep vein thrombosis than in those without, although the differences were not significant (from 14.8 +/- 11.2 ng/mL to 36.2 +/- 19.1 ng/mL in the former group and from 13.6 +/- 3.3 ng/mL to 22.4 +/- 5.1 ng/mL in the latter, p = NS). On the 45th day after surgery the mean value of the thrombin-antithrombin III complexes reduced less in patients with deep vein thrombosis (up to 9.9 +/- 1.9 ng/mL and to 25.2 +/- 17.2 ng/mL, respectively, p = NS). In addition, thrombin-antithrombin III complexes remained over the level reached on the fifth day only in the patients who developed deep vein thrombosis. On the 45th day after surgery, thrombin-antithrombin III complexes exhibited a sensitivity of 17%, a specificity of 86%, and an accuracy of 78% in differentiating the presence and absence of deep vein thrombosis as compared with phlebography. We conclude that after total hip replacement (a) serial measurement of the thrombin-antithrombin III complexes does not appear helpful in predicting venous thromboembolism during hospitalization, and (b) measurement of thrombin-antithrombin III complexes has a low diagnostic accuracy in diagnosing delayed deep vein thrombosis. However, the greater and persistent increase of thrombin-antithrombin III complexes level in patients who developed deep vein thrombosis may deserve further investigations.

Prolonged prophylaxis with unfractioned heparin is effective to reduce delayed deep vein thrombosis in total hip replacement.

The aim of this study was to assess the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) until 45 days after elective total hip replacement (THR) and the efficacy of prolonged unfractioned heparin (UH) prophylaxis up to postoperative day 30. To this end 79 of 96 patients admitted consecutively to the University Hospital of Pisa for THR were randomly assigned to short- or long-term UH prophylaxis. Sixty-one patients completed the study: 28 of them received short-term prophylaxis (subcutaneous UH 15,000 IU/24 h for 15 days) and 33 prolonged prophylaxis (subcutaneous UH 15,000 IU/24 h for 30 days). Lower limb phlebography was performed in all patients on day 45 after THR. DVT was demonstrated in 10 (16.3%) cases after hospital discharge. Among them, 2 patients also had symptomatic PE. The incidence of DVT was 21.4% in short- and 12.1% in long-term UH-treated patients. The incidence of only proximal DVT was 17.8% in short- and 3.0% in long-term UH-treated patients; although the difference was only close to significance (p = 0.085), the relative risk of developing proximal DVT was about six times greater in the former group of patients. We concluded that the risk for thromboembolism persists at least until 45 days after surgery in patients subjected to THR. Prophylaxis with UH given up to postoperative day 30 appears more effective and safer in reducing the delayed thromboembolic risk compared to prophylaxis with UH given up to discharge only.

Resolution of pulmonary embolism: effect of therapy and putative age of emboli.

The purpose of this study was to evaluate functional and scintigraphic improvement in patients with pulmonary embolism (PE) according to the kind of treatment and the putative age of the emboli. The study includes 20 patients with both scintigraphic and angiographic diagnosis of PE enrolled in Pisa as a part of two previous multicenter trials: PAIMS 2 and BAPE. All patients were admitted to the Pulmonary Unit of the University of Pisa and treated with recombinant tissue-type plasminogen activator (rt-PA) plus heparin (H) (n = 10) or with H alone (n = 10). Results confirmed previous data, namely that perfusion damage decreases significantly from embolization to 7 days later in both patients treated with rt-PA + H and H alone (p < 0.001), although patients treated with rt-PA + H have a significantly higher perfusion restoration (p < 0.001) and a standard PaO2 increase (p < 0.01). Interestingly, our data also showed that the putative age of the emboli does not influence the efficacy of rt-PA + H treatment, while it does influence that of H treatment alone; in other words, rt-PA + H therapy may act efficaciously not only in fresh, but also in old pulmonary emboli.